Pretreatment Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase Predict the Prognosis of Metastatic Cervical Cancer Treated with Combination Immunotherapy

Table 2

Correlation between the objective response rate and clinicopathological factors in patients with cervical cancer treated with combination immunotherapy.

Variables	ORR (%)	OR (95% CI)
Age (<50 vs. ≥50 years)	68.75 vs. 55.26	0.561 (0.210–1.502)	0.250
Histology (squamous cell carcinoma vs. adenocarcinoma)	68.52 vs. 43.75	0.389 (0.125–1.214)	0.104
Disease status (local recurrence vs. distant metastasis)	59.26 vs. 62.79	1.160 (0.433–3.109)	0.768
Prior radiotherapy (yes vs. no)	58.93 vs. 71.43	1.742 (0.486–6.241)	0.394
Line of immunotherapy (<3 vs. ≥3)	69.57 vs. 45.83	0.370 (0.134–1.026)	0.056
NLR (<5.33 vs. ≥5.33)	78.26 vs. 53.19	0.316 (0.100–0.991)	0.048
PLR (<297.92 vs. ≥297.92)	70.00 vs. 58.00	0.592 (0.195–1.794)	0.354
MLR (<0.29 vs. ≥0.29)	80.00 vs. 56.36	0.323 (0.082–1.274)	0.107
SCC-Ag (<2.85 vs. ≥2.85)	68.57 vs. 54.29	0.544 (0.205–1.444)	0.222
AGR (<1.80 vs. ≥1.80)	56.90 vs. 83.33	3.788 (0.761–18.849)	0.104
LDH (<195.00 vs. ≥195.00)	67.31 vs. 44.44	0.389 (0.130–1.162)	0.091
ALP (<87.50 vs. ≥87.50)	57.14 vs. 65.71	1.437 (0.547–3.781)	0.462

Abbreviations: AGR, albumin-to-globulin ratio; ALP, alkaline phosphatase; CI, confidence interval; LDH, lactate dehydrogenase; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; ORR, objective response rate; PLR, platelet-to-lymphocyte ratio; SCC-Ag, squamous cell carcinoma-associated antigen.